Jakavi 5 mg (Ruxolitinib Tablet) 5mg

Jakavi 5 mg (Ruxolitinib) tablets are prescribed for myelofibrosis and polycythemia vera symptom management. This JAK inhibitor helps reduce spleen size and disease-related discomfort. Store at room temperature away from moisture. Always follow healthcare provider guidance.

Strength

5mg

Pack Size

60s

Storage

Ambient

Manufacturer / TM Owner

Novartis Pharma Stein AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Jakavi 5 mg tablets contain ruxolitinib, a JAK inhibitor used to treat myelofibrosis and polycythemia vera in adults. It helps reduce enlarged spleen size and symptoms like fatigue or night sweats. Patients with these blood disorders often benefit from its targeted action on overactive JAK pathways.

Side Effects

Many patients notice reduced spleen size and improved energy levels after starting Jakavi 5 mg. Some experience mild gastrointestinal effects like nausea or diarrhea, especially early in treatment. These effects are usually temporary and manageable with standard care.

Precautions & Warnings

Keep Jakavi 5 mg in a cool, dry place away from direct sunlight. Avoid crushing or splitting tablets unless advised by a healthcare professional. Inform your doctor about any ongoing infections or liver conditions before use. Regular blood tests may be needed during treatment.

Avoid Interactions

Jakavi 5 mg may interact with strong CYP3A4 inhibitors or inducers, affecting its levels in the body. Grapefruit products can increase ruxolitinib levels, while St. John’s wort may reduce them. Discuss all medications and supplements with your healthcare provider to avoid potential interactions.

References

Frequently Asked Questions

Jakavi 5 mg (ruxolitinib) is used to treat myelofibrosis and polycythemia vera in adults by reducing spleen size and disease-related symptoms.

Store Jakavi 5 mg at room temperature, away from moisture and heat. Keep the container tightly closed when not in use.

Always consult your doctor before combining Jakavi 5 mg with other drugs, as interactions may occur with CYP3A4 inhibitors or inducers.

Common effects may include nausea, diarrhea, or fatigue, especially when starting treatment. These are usually temporary.

Jakavi 5 mg may not be suitable for people with certain infections or liver conditions. Discuss your medical history with a healthcare provider.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.